Answer
Serevent Evohaler (salmeterol xinafoate) is indicated for regular symptomatic add-on treatment of reversible airways obstruction in asthma, including nocturnal asthma, inadequately controlled on inhaled corticosteroids according to current guidelines, for prevention of exercise-induced asthma, and for treatment of COPD.
Sources for this answer
- Serevent EvohalerGlaxoSmithKline UK · emc · SmPC §4.1 Therapeutic Indications · Version 17Document updated
Sources checked